Clinical trials: Acute Non-Lymphocytic Leukemia
Hematological Malignancy, Acute Leukemia in Remission
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA) expanded cord blood stem cells defined by the lack of serious infusion reactions or graft failure in patients with hematological malignancies…
- Conditions
- Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
- Trial name
- NCT03885947
- Testing
- Cord blood stem cells, Valproic Acid, Fludarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Alla Keyzner
Stem Cell Transplantation, Myelodysplastic Syndromes
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing…
- Conditions
- Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT05968963
- Testing
- Mindfulness-based Music Therapy (MBMT), Mindfulness Meditation (MM)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Miami
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
The objective of this study is to describe the observed safety profile of Xospata® 40 mg tablet when administered in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea.
- Trial name
- NCT04691648
- Testing
- Gilteritinib Exposure
- Where
- 10 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Astellas Pharma Korea, Inc.
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Blood disorders such as leukemia or lymphoma or hemoglobinopathies can benefit from receiving an allogeneic (meaning that the cells are from a donor) stem cell transplant. Stem cells are created in the bone marrow.
- Conditions
- Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00579111
- Testing
- Campath, Busulfan, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
AML (Acute Myelogenous Leukemia), Down Syndrome (DS)
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
This prospective non-randomized multicenter trial created based on protocol ML DS 2006 and aimed at standardization of current therapy approaches and creating a national network for diagnostic, treatment and monitoring of…
- Trial name
- AML-DS-2025 (NCT07232134)
- Testing
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk…
- Trial name
- NCT05554393
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 187 sites in United States, Canada and 1 more
- Volunteers
- 153 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Chronic, AML
Stem Cell Transplant for Hematological Malignancy
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood.
- Conditions
- Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS
- Trial name
- NCT00176930
- Testing
- Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myeloid, Acute
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and to characterize the safety and tolerability…
- Trial name
- NCT02715011
- Testing
- JNJ-63709178
- Where
- 10 sites in United States, Spain
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and…
- Trial name
- NCT02989844
- Testing
- N-803
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment.
- Trial name
- NCT07306832
- Testing
- Pivekimab Sunirine
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 18 people
- Sponsor
- AbbVie
Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
This study is testing a new type of treatment called anti-CD19 CAR-T cell therapy for adults with certain blood cancers that have returned or did not respond to previous treatments.
- Trial name
- NCT06705530
- Testing
- Hem101
- Where
- Russia
- Volunteers
- 58 people
- Sponsor
- National Research Center for Hematology, Russia
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Leukemia, Lymphoma
Immunotoxin in Treating Patients With Leukemia or Lymphoma
RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002765
- Testing
- LMB-2 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Lomustine and Intermediate Dose Cytarabine in Older Patients With AML
A multicenter randomized trial was performed comparing induction therapy (IC: Idarubicin and Cytarabine, 5+7) to ICL (the same drugs plus lomustine (CCNU), 200mg\m2 orally at day 1).
- Trial name
- NCT00480064
- Testing
- Lomustine, intermediate dose cytarabine
- Where
- France
- Volunteers
- 360 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01035307
- Testing
- gene expression analysis, microarray analysis, proteomic profiling
- Volunteers
- 90 people
- Sponsor
- Children's Oncology Group
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.